Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis​

Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis​

RSS » New York Times News » NYTHealth

Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis​

September 24, 2025

22HS-KENVUE-01-bczl-mediumSquareAt3X-MSCGtK-rss

 Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism.  

Creator: The New York Times (NYTHealth)

Source URL

Related Posts

  • Public Awareness and Engagement
Vaccination and Public Health: Protecting Generations
Vaccination and Public Health
  • Sustainable Practices
LEED Certification Standards: Building for a Sustainable Future
LEED Certification Standards
  • Research and Innovation
Natural Compounds in Drug Development: New Medicine Frontiers
Natural Compounds in Drug Development

Most Recent

  • Book and Article Reviews
One Health Book Review: A Comprehensive Analysis 
One Health Book Review
  • Careers
Value of MPH in One Health: Career Benefits and Impact
Value of MPH in One Health
  • Community Stories
Malaria Control Strategies: One Health in Action
Malaria Control Community Stories

Spheres of Focus

Infectious Diseases

Climate & Disasters

Food &
Water

Natural
Resources

Built
Environments

Technology & Data

Featured Posts